ValiRx PLC banner

ValiRx PLC
Goodwill

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

ValiRx PLC
Goodwill Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Goodwill CAGR 3Y CAGR 5Y CAGR 10Y
ValiRx PLC
LSE:VAL
Goodwill
£1.6m
CAGR 3-Years
0%
CAGR 5-Years
0%
CAGR 10-Years
N/A
Bicycle Therapeutics PLC
NASDAQ:BCYC
Goodwill
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Immunocore Holdings PLC
NASDAQ:IMCR
Goodwill
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Compass Pathways PLC
NASDAQ:CMPS
Goodwill
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Genus PLC
LSE:GNS
Goodwill
£101.9m
CAGR 3-Years
-3%
CAGR 5-Years
0%
CAGR 10-Years
3%
Oxford BioMedica PLC
LSE:OXB
Goodwill
£0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

ValiRx PLC
Glance View

Market Cap
2.3m GBX
Industry
Biotechnology

ValiRx Plc is a life science company, which focuses on clinical stage cancer therapeutic development, taking proprietary and novel technology for precision medicines towards commercialization and partnering. The company is headquartered in Nuneaton, Warwickshire and currently employs 10 full-time employees. The company went IPO on 2000-02-28. The firm is engaged in the development of oncology therapeutics and companion diagnostics. The company focuses on the development of treatments in cancer and women’s health. Its product pipeline includes VAL201, VAL301, VAL401 and BC201. Its VAL201 is an anti-cancer therapeutic drug, which is in clinical trials for the treatment of prostate cancer. Its VAL301 for the treatment of women with endometriosis. Its VAL401 is the reformulation of a generic drug for treatment of a chronic non-oncology disease in an oral capsule. Its BC201 is a combination of the peptide ingredient of VAL201 with active components to dampen this excessive immune response and consequently improve severe symptoms of Covid-19. The company operates through divisional companies, including ValiPharma and ValiSeek.

VAL Intrinsic Value
0.03 GBX
Overvaluation 89%
Intrinsic Value
Price GBX0.31

See Also

What is ValiRx PLC's Goodwill?
Goodwill
1.6m GBP

Based on the financial report for Jun 30, 2025, ValiRx PLC's Goodwill amounts to 1.6m GBP.

What is ValiRx PLC's Goodwill growth rate?
Goodwill CAGR 5Y
0%

Over the last year, the Goodwill growth was 0%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett